EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review

Chang Li, Saadia A Faiz, Megan Boysen-Osborn, Ajay Sheshadri, Monica K Wattana

Western Journal of Emergency Medicine · 07.02.2025 · 26 (2)

DOI: 10.5811/westjem.20305 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Western Journal of Emergency Medicine, online erschienen am 07.02.2025. Verfasst von Chang Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: McGovern Medical School at University of Texas Health, Divisions of Pulmonary, Critical Care Medicine and Sleep Medicine, Houston, Texas. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Pneumonia. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICI), such as pembrolizumab, nivolumab, durvalumab and ipilimumab, have significantly enhanced survival rates for multiple cancer types such as non-small cell lung cancer, melanoma, Hodgkin lymphoma, and breast cancer, and they have emerged as an adjunct or primary therapy for malignant disease. Approximately 40% of patients with cancer on ICI therapy experience side effects called immune-related adverse events (irAE). While not the most common, pulmonary toxicities can be rapidly progressive, potentially fatal, and pose a three-fold increased risk for requiring intensive care unit-level of care. Pneumonitis is a focal or diffuse inflammation of the lung parenchyma, and clinical manifestations may be highly variable. While the onset is generally observed 6–12 weeks after the initiation of therapy, drug toxicity can develop rapidly within days after the first infusion or many months into therapy. Pneumonitis symptoms can be subtle or non-specific; therefore, a thorough and systematic evaluation considering other possible etiologies is crucial. Moreover, extrapulmonary findings, such as skin lesions, colitis, or endocrinopathies, should raise suspicion for irAE as drug toxicity can affect multiple organs simultaneously. Due to the significant overlap of clinical features between ICI-associated pneumonitis and respiratory infections, it can be challenging to differentiate the two conditions based on clinical presentation alone. A multidisciplinary approach to management is recommended for the treatment of ICI-associated pneumonitis, and classification of severity helps to guide interventions. Treatment options in more severe cases include systemic immunosuppression. Given the increased use of ICIs and greater probability that patients with ICI-associated pneumonitis will be seen in the emergency department, we aimed to provide a comprehensive framework for the diagnosis and management. In addition, identifying potential challenges in diagnosis and/or other contributors of respiratory symptoms and radiographic manifestations is highlighted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsPneumoniaHumansNeoplasmsAntibodies, Monoclonal, Humanized

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • McGovern Medical School at University of Texas Health, Divisions of Pulmonary, Critical Care Medicine and Sleep Medicine, Houston, Texas.
  • The University of Texas MD Anderson Cancer Center, Department of Pulmonary Medicine, Houston, Texas.
  • University of California Irvine School of Medicine, Department of Emergency Medicine, Irvine, California.
  • The University of Texas MD Anderson Cancer Center, Department of Emergency Medicine, Houston, Texas.

Zitieren

APA

Li, C., Faiz, S. A., Boysen-Osborn, M., Sheshadri, A., & Wattana, M. K. (2025). Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review. Western Journal of Emergency Medicine, 26(2). https://doi.org/10.5811/westjem.20305

Vancouver

Li C, Faiz SA, Boysen-Osborn M, Sheshadri A, Wattana MK. Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review. Western Journal of Emergency Medicine. 2025;26(2). doi:10.5811/westjem.20305

BibTeX
@article{Li2025,
  author = {Li, Chang and Faiz, Saadia A and Boysen-Osborn, Megan and Sheshadri, Ajay and Wattana, Monica K},
  title = {Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review},
  journal = {Western Journal of Emergency Medicine},
  year = {2025},
  volume = {26},
  number = {2},
  doi = {10.5811/westjem.20305}
}
Kostenlos starten →